News & publications
News from Aminex.
Discover the research, milestones, and stories shaping the future of Aminex.
- June 2026
-
March 2026
Press release
Aminex Therapeutics Receives Second FDA Orphan Drug Designation for AMXT 1501 for Malignant Glioma
Read More -
February 2026
Press release
Aminex Therapeutics Announces Multiple Sites Activated for Phase 1b/2 Clinical Trial
Read More - November 2025
- October 2025
- October 2025
- September 2025
-
March 2025
Publication
Molecular Oncology: The polyamine transporter ATP13A3 mediates DFMO-induced uptake
Read More -
February 2025
Publication
International Journal of Cancer: Polyamine depletion limits progression of acute leukaemia
Read More - September 2024
-
April 2023
Announcement
Aminex completes Phase 1a portion of clinical trial evaluating AMXT-1501 and DFMO
-
November 2022
Announcement
Aminex Enrolls First Patient in Phase 1B Trial of AMXT-1501 and DFMO
-
August 2022
Announcement
Aminex Therapeutics Completes Enrollment in Phase 1A portion of Clinical Trial Evaluating AMXT 1501 and DFMO
-
February 2021
Press release
Sydney Researchers Identify Potential New Drug Treatment for Fatal Childhood Cancer
Read More - January 2019
- June 2018
- November 2015
Historical PDFs and press releases retain their original wording. Several older items include statements superseded by the current website brief.